{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:53:56Z","timestamp":1747169636469,"version":"3.40.5"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.psychres.2015.03.019","type":"journal-article","created":{"date-parts":[[2015,4,6]],"date-time":"2015-04-06T06:16:29Z","timestamp":1428300989000},"page":"26-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimization of psychopharmacotherapy for schizophrenia in a male, locked, non-acute unit serving for persistently ill patients over one year"],"prefix":"10.1016","volume":"228","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5147-1684","authenticated-orcid":false,"given":"Takefumi","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Tsunoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Ishizuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2015.03.019_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.schres.2004.01.016","article-title":"Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials","volume":"70","author":"Basan","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.psychres.2015.03.019_bib2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.schres.2008.01.013","article-title":"Quetiapine at high doses for the treatment of refractory schizophrenia","volume":"101","author":"Boggs","year":"2008","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.psychres.2015.03.019_bib3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.psychres.2015.03.019_bib4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1586\/ern.09.54","article-title":"Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?","volume":"9","author":"Citrome","year":"2009","journal-title":"Expert Review of Neurotherapeutics"},{"key":"10.1016\/j.psychres.2015.03.019_bib5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/schbul\/sbn018","article-title":"Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials","volume":"35","author":"Correll","year":"2009","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.psychres.2015.03.019_bib6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/acps.12233","article-title":"Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patients","volume":"130","author":"Davis","year":"2014","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1016\/j.psychres.2015.03.019_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/eb-2014-101813","article-title":"Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective","volume":"17","author":"Dold","year":"2014","journal-title":"Evidence Based Mental Health"},{"key":"10.1016\/j.psychres.2015.03.019_bib8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000135641","article-title":"Typical and atypical antipsychotics - The misleading dichotomy. Results from the Working Group \u2018Drugs in Psychiatry\u2019 (AGATE)","volume":"57","author":"Fischer-Barnicol","year":"2008","journal-title":"Neuropsychobiology"},{"issue":"9","key":"10.1016\/j.psychres.2015.03.019_bib9","first-page":"CD003079","article-title":"Benzodiazepines for psychosis-induced aggression or agitation","volume":"18","author":"Gillies","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.psychres.2015.03.019_bib10","series-title":"ECDEU Assessment Manual for Psychopharmacology-Revised (DHEW Publ No ADM 76\u2013338)","first-page":"218","author":"Guy","year":"1976"},{"key":"10.1016\/j.psychres.2015.03.019_bib11","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1192\/bjp.bp.111.105833","article-title":"Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation","volume":"201","author":"Howes","year":"2012","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2015.03.019_bib12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1080\/j.1440-1614.2004.01340.x","article-title":"An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand","volume":"38","author":"Humberstone","year":"2004","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2015.03.019_bib13","first-page":"887","article-title":"Dose equivalence of psychotropic drugs. Part XXI: dose equivalence of novel antipsychotics","volume":"11","author":"Inagaki","year":"2008","journal-title":"Japanese Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.psychres.2015.03.019_bib14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. a double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Archives of General Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2015.03.019_bib15","first-page":"CD003834","article-title":"Lithium for schizophrenia","volume":"18","author":"Leucht","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.psychres.2015.03.019_bib16","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.psychres.2015.03.019_bib17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.genhosppsych.2012.01.019","article-title":"Antipsychotic polypharmacy: a needle in a haystack?","volume":"34","author":"L\u00f3pez de Torre","year":"2012","journal-title":"General Hospital Psychiatry"},{"key":"10.1016\/j.psychres.2015.03.019_bib18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","article-title":"Update on typical and atypical antipsychotic drugs","volume":"64","author":"Meltzer","year":"2013","journal-title":"Annual Review of Medicine"},{"key":"10.1016\/j.psychres.2015.03.019_bib19","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.4088\/JCP.v68n1115","article-title":"The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update","volume":"68","author":"Moore","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.psychres.2015.03.019_bib20","doi-asserted-by":"crossref","first-page":"566","DOI":"10.4088\/JCP.08m04912gre","article-title":"Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients","volume":"71","author":"Procyshyn","year":"2010","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.psychres.2015.03.019_bib21","first-page":"323","article-title":"Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia","volume":"18","author":"Suzuki","year":"2003","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1016\/j.psychres.2015.03.019_bib22","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.pnpbp.2003.11.006","article-title":"A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia","volume":"28","author":"Suzuki","year":"2004","journal-title":"Progress in Neuropsychopharmacology and Biological Psychiatry"},{"key":"10.1016\/j.psychres.2015.03.019_bib23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1017\/S1461145703004012","article-title":"Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia","volume":"7","author":"Suzuki","year":"2004","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2015.03.019_bib24","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s00213-005-0018-3","article-title":"Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia","volume":"181","author":"Suzuki","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.psychres.2015.03.019_bib25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00213-007-0872-2","article-title":"How effective is it to sequentially switch among olanzapine, quetiapine and risperidone? - A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting","volume":"195","author":"Suzuki","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.psychres.2015.03.019_bib26","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/hup.959","article-title":"Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone","volume":"23","author":"Suzuki","year":"2008","journal-title":"Human Psychopharmacology"},{"key":"10.1016\/j.psychres.2015.03.019_bib27","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.schres.2008.08.013","article-title":"Novel rating scales for schizophrenia - Targeted Inventory on Problems in Schizophrenia (TIP-Sz) and Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz)","volume":"106","author":"Suzuki","year":"2008","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.psychres.2015.03.019_bib28","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/hup.1073","article-title":"Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia","volume":"24","author":"Suzuki","year":"2009","journal-title":"Human Psychopharmacology"},{"key":"10.1016\/j.psychres.2015.03.019_bib29","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/JCP.0b013e3181f0bae1","article-title":"Magnitude of rater differences in assessment scales for schizophrenia","volume":"30","author":"Suzuki","year":"2010","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.psychres.2015.03.019_bib30","first-page":"18","article-title":"Which rating scales are regarded as \u2018the standard\u2019 in clinical trials for schizophrenia? A critical review","volume":"44","author":"Suzuki","year":"2011","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1016\/j.psychres.2015.03.019_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psychres.2012.02.013","article-title":"Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation","volume":"197","author":"Suzuki","year":"2012","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.psychres.2015.03.019_bib32","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/hup.2421","article-title":"A review on schizophrenia and relapse - A quest for user-friendly psychopharmacotherapy","volume":"29","author":"Suzuki","year":"2014","journal-title":"Human Psychopharmcology"},{"key":"10.1016\/j.psychres.2015.03.019_bib33","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1017\/S146114571000163X","article-title":"Adjunctive benzodiazepine treatment of hospitalized schizophrenia patients in Asia from 2001 to 2008","volume":"14","author":"Tor","year":"2011","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2015.03.019_bib34","first-page":"679","article-title":"Do we prescribe what patients prefer? Pilot study to assess patient preferences for medication regimen characteristics","volume":"6","author":"Witticke","year":"2012","journal-title":"Patient Preference and Adherence"},{"key":"10.1016\/j.psychres.2015.03.019_bib35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/s-0031-1286345","article-title":"Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001\u20132009)","volume":"45","author":"Xiang","year":"2012","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.psychres.2015.03.019_bib36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1055\/s-0031-1301292","article-title":"Adjunctive mood stabilizer and benzodiazepine use in older Asian patients with schizophrenia, 2001-2009","volume":"45","author":"Xiang","year":"2012","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.psychres.2015.03.019_bib37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1055\/s-2004-815471","article-title":"Combination of clozapine and amisulpride in treatment-resistant schizophrenia\u2014case reports and review of the literature","volume":"37","author":"Zink","year":"2004","journal-title":"Pharmacopsychiatry"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178115001444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178115001444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T09:41:45Z","timestamp":1621071705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178115001444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0165178115001444"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2015.03.019","relation":{},"ISSN":["0165-1781"],"issn-type":[{"type":"print","value":"0165-1781"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization of psychopharmacotherapy for schizophrenia in a male, locked, non-acute unit serving for persistently ill patients over one year","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2015.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}